Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Bionano Genomics, Inc.

Ticker
BNGO
Sector
Industry
Report date
November 11, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings call transcripts for Q1 through Q3 2026, reporting operational updates and financial results. News coverage highlights include proposed Medicare coverage for genome-wide hematologic cancer testing and ongoing adoption of OGM technology.

Recent developments:
  • Bionano Genomics reported Q3 2026 earnings and operational updates in November 2026 [N1].
  • The company held Q2 2026 earnings call in August 2026 discussing business progress [N4].
  • Q1 2026 earnings transcript released in June 2026 detailed financial and operational performance [N5].
  • In May 2026, Bionano reported Q1 loss but topped revenue estimates [N6].
  • News in September 2026 highlighted Bionano among biotech stocks making gains and discussed OGM studies revealing high-risk genomic alterations missed by standard cytogenetics [N3].
  • In September 2026, Bionano announced proposed Medicare coverage for genome-wide hematologic cancer testing [N3].
Overview

Bionano Genomics, Inc. develops and commercializes genome analysis solutions centered on Optical Genome Mapping (OGM) technology. Its product portfolio includes OGM instruments (Saphyr and Stratys systems), consumables such as flowcells, and software platforms like VIA that integrate multiple genomic data types for comprehensive analysis. The company serves research and clinical laboratories, pharmaceutical and biotech firms, and contract research organizations globally. Bionano also provides diagnostic testing services through its Bionano Laboratories business. The company operates a reagent rental program offering instruments at no upfront cost in exchange for consumable purchases. Its market opportunity spans cytogenetics, molecular pathology, cell and gene therapy research, and broader pathology applications. Bionano reported total revenues of $28.5 million in 2025, with a slight decline from the prior year, driven by lower instrument sales but growth in consumables. The installed base of OGM systems increased by 4.3% to 387 units by end-2025. The company has disclosed substantial doubt about its ability to continue as a going concern within 12 months without additional capital. It faces risks from macroeconomic and geopolitical factors including supply chain challenges and inflation.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Bionano Genomics, Inc. is a provider of genome analysis solutions including Optical Genome Mapping systems, software, and diagnostic services. The company reported $28.5 million in total revenue for 2025, a 7% decrease from 2024, with a net loss of $26.4 million for the year. As of September 30, 2026, it held $4.36 million in cash and equivalents with a current ratio of 2.07. The installed base of OGM systems grew modestly to 387 units by end of 2025. Bionano focuses on increasing utilization of existing instruments rather than new placements. The company faces risks including macroeconomic uncertainties and substantial doubt about its ability to continue as a going concern without additional financing.

Scenarios for BNGO

Bull case model:

Bionano Genomics has demonstrated growth in its installed base of OGM systems and consumables revenue, indicating adoption of its technology in research and clinical settings. Its platform-agnostic software and integrated solutions address complex genomic analysis needs. The company’s reagent rental program supports recurring consumable sales. Recent news highlights ongoing operational activity and potential Medicare coverage proposals for its diagnostic testing, which could enhance market access. Continued investments in R&D and expanding applications in cytogenomics and cell and gene therapy markets may support business development.

Bear case model:

Bionano Genomics faces substantial doubt about its ability to continue as a going concern without additional financing, reflecting ongoing operating losses and cash burn. Total revenue declined 7% in 2025, with significant decreases in instrument sales and service revenue. The company is exposed to macroeconomic and geopolitical risks including supply chain disruptions and inflationary pressures. The genomics market is competitive and rapidly evolving, with technological and regulatory uncertainties. The company’s reliance on capital raises and potential restructuring poses execution risks.

Moat:

Bionano Genomics' moat is based on its proprietary Optical Genome Mapping technology and integrated software platform that consolidates multiple genomic data types for comprehensive analysis. Its reagent rental model encourages consumable sales and customer lock-in. The company's installed base of OGM systems and ongoing investments in research and development support its competitive position. Additionally, its diagnostic services and proprietary nucleic acid extraction technology contribute to differentiation. However, the company operates in a competitive and evolving genomics market with significant technological and regulatory challenges.

Risks overview
Risks summary
The most significant risk is the company's substantial doubt about its ability to continue as a going concern without additional financing, compounded by macroeconomic uncertainties and competitive pressures.
Risks details:

• Going Concern Risk: The company disclosed substantial doubt about its ability to continue as a going concern within 12 months without additional capital financing, indicating liquidity and operational risks.
• Macroeconomic and Geopolitical Risks: Bionano faces risks from adverse geopolitical developments, inflation, supply chain challenges, and uncertain market conditions that could materially impact operations and financial results.
• Revenue Concentration and Growth Risks: Revenue declined 7% in 2025, driven by decreases in instrument sales and service revenue, with growth concentrated in consumables. The shift in strategy to focus on utilization over new instrument placements may limit revenue expansion.
• Competitive and Technological Risks: The genomics market is competitive with rapid technological change. Bionano must continue to innovate and maintain regulatory compliance to sustain its market position.

FINAL FORECAST FOR BNGO

Final take one line
Bionano Genomics has detailed disclosures and recent operational updates showing modest growth in installed base and consumables amid ongoing financial challenges and liquidity risks.
Final take 12 to 24 month view

Business trends: Modest growth in installed base and consumables revenue with strategic focus on utilization of existing instruments; ongoing macroeconomic and geopolitical risks impacting supply chain and costs.
Execution milestones: Continued quarterly earnings disclosures and operational updates; progress on Medicare coverage proposals for diagnostic testing; maintaining installed base growth.
Key risks: Substantial doubt about going concern status without additional financing; competitive genomics market; revenue concentration risks; macroeconomic uncertainties affecting operations.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Bionano Genomics, Inc. provides genome analysis solutions including Optical Genome Mapping (OGM) systems, diagnostic services, and software for research and clinical applications.
  • The company offers OGM systems such as the Saphyr and Stratys systems, consumables including flowcells, and software solutions like VIA for integrated genomic data analysis.
  • Bionano's customers include academic and governmental research institutions, clinical laboratories, pharmaceutical, biotechnology, and contract research companies.
  • The installed base of OGM systems grew to 387 units as of December 31, 2025, a 4.3% increase from 371 units in 2024.
  • Annual product revenue was approximately $26.7 million for 2025, slightly down 1% from 2024, with consumables revenue increasing 9% to $14.0 million and instrument revenue decreasing 21% to $6.4 million.
  • Service and other revenue declined 53% to $1.8 million in 2025 compared to 2024.
  • Total revenue decreased 7% to $28.5 million in 2025 from $30.8 million in 2024.
  • The company incurred a net loss of $26.4 million for the year ended December 31, 2025, an improvement from a $112.0 million loss in 2024.
  • As of September 30, 2026, Bionano had $4.36 million in cash and cash equivalents and a current ratio of 2.07, indicating liquidity to cover short-term liabilities.
  • Bionano operates a reagent rental program providing instruments at no cost in exchange for minimum consumable purchases.
  • The company focuses on increasing utilization and adoption of OGM from its existing installed base rather than aggressively placing new instruments.
  • Bionano faces macroeconomic and geopolitical risks including supply chain challenges, inflation, and international trade uncertainties, which have not materially impacted results to date but remain potential risks.
  • The company has disclosed substantial doubt about its ability to continue as a going concern within 12 months without additional capital financing.
  • Bionano's market opportunity includes approximately 10,000 cytogenetic labs worldwide analyzing 10 million samples annually, with an estimated $10 billion annual economic potential for OGM in cytogenomics and cell and gene therapy applications.
  • The company also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology.
  • Bionano's software platform is platform-agnostic and integrates next-generation sequencing, microarray, and OGM data for comprehensive genomic analysis.
  • Recent news includes multiple quarterly earnings call transcripts and reports on Medicare coverage proposals for genome-wide hematologic cancer testing.
  • The company reported Q3 2026 earnings and operational updates in November 2026 [N1][S2].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-23 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-11 | www.nasdaq.com | Bionano Genomics (BNGO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/bionano-genomics-bngo-q3-2026-earnings-call-transcript
  • N2 | 2026-11-06 | www.nasdaq.com | Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates | https://www.nasdaq.com/articles/sarepta-therapeutics-srpt-q3-earnings-lag-estimates
  • N3 | 2026-09-14 | www.nasdaq.com | Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains | https://www.nasdaq.com/articles/biotech-stocks-move-tyra-nasus-bionano-tenaya-make-gains
  • N4 | 2026-08-17 | www.nasdaq.com | Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/bionano-genomics-bngo-q2-2026-earnings-call-transcript
  • N5 | 2026-06-02 | www.nasdaq.com | Bionano (BNGO) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/bionano-bngo-q1-2026-earnings-transcript
  • N6 | 2026-05-13 | www.nasdaq.com | Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/bionano-genomics-inc-bngo-reports-q1-loss-tops-revenue-estimates
  • N7 | 2026-05-12 | www.nasdaq.com | Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/arvinas-inc-arvn-reports-q1-loss-misses-revenue-estimates
  • N8 | 2026-05-07 | www.nasdaq.com | Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1 | https://www.nasdaq.com/articles/lexicon-pharmaceuticals-lxrx-reports-break-even-earnings-q1
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine